Pharmacosmos launches Uniferon injectable iron in the U.S.

March 31, 2011

Pharmacosmos Inc. has announced that its Uniferon® brand of injectable iron for baby pigs will be available for the U.S. market April 1, 2011 following U.S. Food and Drug Administration (FDA) approval. Pharmacosmos will offer both Uniferon® 200 (200mg iron/mL) and Uniferon® 100 (100mg iron/mL) final dosage form (FDF) injectable products to swine producers and livestock veterinarians across the U.S.

Pharmacosmos provides U.S. veterinary market customers with a reliable supply of high quality, FDA-approved, final dosage form (FDF) injectable iron products. In fact, Uniferon® 200 is the only 200mg/mL veterinary iron supplement that is approved by both the FDA and the health authorities in Europe and Asia.

The Uniferon® 200 final dosage form (FDF) Iron Dextran Complex Injection, 200 mg/mL  product is the result of original research and development conducted by Pharmacosmos A/S in Denmark.  In the capable hands of the U.S. swine veterinarians, Uniferon® 200 is an injectable iron supplement that will help prevent or eliminate sub-clinical and full-scale iron deficiency anemia in baby pigs and, in conjunction with an adequate supply of fully nutritious sow's milk during the lactation period, or the pre-weaning phase of growth, will provide for normal, healthy, vigorous growth through the critical pre-weaning period.

Pharmacosmos has a new state-of-the-art manufacturing and research facility in Denmark as a result of an investment of more than 100 million USD in 2003. Today Pharmacosmos is a leader in iron therapy and associated pharmaceutical research. The company develops, manufactures and markets innovative therapies for the treatment of iron deficiency in both humans and animals.

Pharmacosmos has been supplying the U.S. market with high quality FDA approved APIs for human and veterinary use since the mid-1980s.

In recent years there has been an inconsistent supply of veterinary injectable iron dextran products in the U.S. due to the problems associated with previous manufacturers to consistently meet FDA requirements. Pharmacosmos understands these demands and is committed to the high standards of FDA compliance. It has been a major goal with a required investment to assure there is an uninterrupted and quality supply of products to the U.S. market.

As distribution partner in the U.S., Pharmacosmos has appointed Ivesco, a major distribution company which has serviced the swine industry for more than 50 years. For more information regarding availability and pricing of the Uniferon® product line, please contact Ivesco or visit www.ivescollc.com.

About Injectable Iron

Baby pigs are very susceptible to iron deficiency anemia. Therefore, iron deficiency anemia in litters of baby pigs poses a risk to both animal health, welfare, and productivity. An injection of iron shortly after farrowing is an effective and is a globally established "best practices method" utilized to prevent iron deficiency anemia in baby pigs.

About Uniferon 200

Uniferon 200 is a modern and much improved iron hydrogenated dextran, based upon a very low impurity profile formulation, whereby this source of injectable iron for baby pigs has been approved by numerous healthcare authorities for global use.

Pharmacosmos manufactures iron dextran of high quality and unique purity, which is distributed to human and animal drug customers worldwide. Uniferon 200 is the only injectable iron brand for baby pigs approved by healthcare authorities in the EU, in the U.S. and in Asia.

About Pharmacosmos

Pharmacosmos Inc, located in Watchung, NJ as a fully owned subsidiary of Pharmacosmos A/S. is dedicated to the sales of veterinary pharmaceuticals for the treatment and prevention of iron deficiency Anemia, including Uniferon 200.

Headquartered in Holbaek, Denmark, Pharmacosmos A/S is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.

A research-based company, the Pharmacosmos A/S ongoing R&D program focuses on improving the lives of patients with sub-clinical and full-scale iron deficiency anemia. More than 1 billion people live with iron deficiency anemia and it is the leading cause of death for an estimated 180,000 people world-wide every year. This makes sub-clinical and full-scale iron deficiency anemia one of the largest global health challenges of the current time.

Pharmacosmos A/S has subsidiaries in the US, China, Nordics, Germany, UK and Ireland, and its products are marketed in more than 80 countries around the world. The Pharmacosmos A/S manufacturing facilities located in Denmark have supported global healthcare authority approvals, among others, by the Danish Medicines Agency and the U.S. FDA.